Goldman Sachs Group Inc. Trims Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Goldman Sachs Group Inc. reduced its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 652,154 shares of the life sciences company’s stock after selling 31,139 shares during the period. Goldman Sachs Group Inc. owned approximately 0.83% of Integra LifeSciences worth $28,401,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Signaturefd LLC grew its position in shares of Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares in the last quarter. Hexagon Capital Partners LLC grew its position in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 370 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Integra LifeSciences during the 3rd quarter valued at $47,000. Covestor Ltd grew its position in shares of Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 921 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at $131,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IART shares. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Wells Fargo & Company lowered shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $45.00 to $25.00 in a research report on Tuesday, May 7th. Truist Financial cut their target price on shares of Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating for the company in a research report on Tuesday, May 7th. Bank of America cut their target price on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research report on Tuesday, May 7th. Finally, JMP Securities cut their target price on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average target price of $35.00.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $29.51 on Monday. The company has a quick ratio of 3.35, a current ratio of 4.68 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $2.33 billion, a PE ratio of 59.02, a P/E/G ratio of 1.04 and a beta of 1.17. The firm has a fifty day simple moving average of $28.83 and a two-hundred day simple moving average of $36.06. Integra LifeSciences Holdings Co. has a twelve month low of $22.36 and a twelve month high of $46.75.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The business had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.74 earnings per share. Research analysts expect that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current year.

Insider Activity

In other news, Chairman Stuart Essig acquired 52,641 shares of the stock in a transaction dated Thursday, May 23rd. The stock was purchased at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.10% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.